A Revolution in Early Cancer Detection

GRAIL’s mission is to detect cancer early, when it can be cured.

1 in 2 men and 1 in 3 women are diagnosed with some form of cancer in America in their lifetime

71% of cancers today don’t have routine screening

In 2021, it is estimated that more than 600,000 Americans will be diagnosed with cancer each day

Recommended screening only exists for 5 cancer types and many cancers are detected too late

“As a powerful cancer screening tool, ctDNA could be used for early cancer detection. This could mean detecting cancer prior to a cancer diagnosis in an asymptomatic population, or detecting early recurrence, or the degree or burden of disease in patients that have already been diagnosed with cancer.”

– Friends of Cancer Research White Paper, Exploring the Use of Circulating Tumor DNA as a Monitoring Tool for Drug Development

---

1 https://www.cdc.gov/chronicdisease/resources/publications/factsheets/cancer.htm
3 https://cancerstatisticscenter.cancer.org/#!/
In order to achieve benefits of early detection while minimizing harms at a population scale, multi-cancer early detection tests should have:

- **Low false positives**: achieved through high specificity
- **Localizing ability**: identifies anatomic location to direct appropriate diagnostic work-up
- **Limited overdiagnosis**: preferential detection of clinically significant cancers

### THE RESULT

GRAIL has created Galleri, a simple blood test that can detect more than 50 types of cancers.

Galleri will help:
- detect cancer at early stages, sometimes before symptoms even appear
- complement existing cancer screening paradigms
- detect cancers at a false positive rate of less than 1%
- predict the cancer signal of origin to guide next steps

### THE SCIENCE

GRAIL is generating scientific and clinical evidence through clinical studies enrolling more than 145,000 participants in what we believe is the largest clinical programs in genomic medicine to date.

### THE TECHNOLOGY

Through tremendous advancements in the fields of genomics, next-generation sequencing, machine learning, and artificial intelligence, GRAIL uses technology to find and sequence tiny bits of DNA in the blood. The technology can determine whether or not a cancer signal is present and if so, predict the cancer signal origin with high accuracy.

GRAIL’s multi-cancer early detection technology has the potential to detect deadly cancers early, when they are most treatable. Equipped with this powerful information from a simple blood draw, doctors may have the opportunity to step in and administer interventions before the cancer has a chance to spread.

---

**Galleri, the first of its kind multi-cancer early detection test, will be launched in 2021.**

---